Related Experiment Video

Updated: Jun 27, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Cardiovascular effects of antiretroviral drugs: clinical review

Pasquale Perrone Filardi1, Stefania Paolillo, Caterina Marciano

  • 1Department of Clinical Medicine, Cardiovascular and Immunological Sciences, Federico II University, Via Pansini, 5 80131 Naples, Italy. fpperron@unina.it

Cardiovascular & Hematological Disorders Drug Targets
|December 17, 2008
PubMed

Insights

Highly active antiretroviral therapy (HAART) for HIV increases cardiovascular risk due to metabolic side effects. Managing these metabolic changes is crucial for improving outcomes in HIV patients.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Highly active antiretroviral therapy (HAART) for HIV is linked to increased cardiac events.
  • Antiretroviral drugs cause metabolic side effects like dyslipidemia and abnormal fat distribution, raising cardiovascular risk in HIV patients.
  • HIV infection, chronic inflammation, and traditional risk factors further elevate cardio- and cerebrovascular event incidence.

Purpose of the Study:

  • To review the metabolic effects of antiretroviral drugs.
  • To examine the contribution of combination antiretroviral therapy to cardiovascular risk in HIV patients.

Main Methods:

  • Review of studies on metabolic side effects of antiretroviral therapy.
  • Analysis of data linking protease inhibitor (PI) exposure to cardiovascular events.
  • Examination of the DAD Study findings on myocardial infarction risk.

Main Results:

  • Studies indicate carotid vascular impairment in patients on protease inhibitors (PI).
  • The DAD Study showed a 26% increased risk of myocardial infarction with HAART, independently associated with PI exposure duration.
  • Metabolic abnormalities associated with antiretroviral drugs contribute significantly to cardiovascular risk.

Conclusions:

  • Assessing metabolic status before HAART initiation is vital.
  • Controlling drug-related metabolic abnormalities can reduce cardiac events.
  • Proactive management of metabolic effects improves prognosis for HIV patients.

More Related Videos

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.